Qlaris Bio appointed Fred Guerard, PharmD, as its president and CEO, according to a press release.
The company is entering phase 3 development of QLS-111, a novel eye drop for lowering IOP in patients with open-angle glaucoma and ocular hypertension (OHT). In a statement to Healio, Guerard said he is coming to the company at an important time, with “promising results” coming out of the phase 2 Osprey and Apteryx clinical trials.
“As QLS-111 advances into phase 3 clinical development, Qlaris Bio is at a pivotal moment — building on encouraging clinical data and a